Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer.
Adult
Aged
Aged, 80 and over
Basic Helix-Loop-Helix Transcription Factors
/ analysis
Biomarkers, Tumor
/ analysis
Carcinoma, Renal Cell
/ diagnosis
Cell Line, Tumor
Chemotherapy, Adjuvant
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Genes, Tumor Suppressor
Humans
Hypoxia-Inducible Factor 1, alpha Subunit
/ analysis
Kidney Neoplasms
/ diagnosis
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Nephrectomy
Prognosis
RNA-Seq
Retrospective Studies
Single-Cell Analysis
Survival Analysis
Tumor-Associated Macrophages
/ immunology
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
15 09 2020
15 09 2020
Historique:
received:
27
11
2019
revised:
20
04
2020
accepted:
22
06
2020
pubmed:
27
6
2020
medline:
15
12
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel-Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have comprehensively examined the clinical relevance of this paradigm. Furthermore, the hypoxia-associated factor (HAF), which regulates the HIFs, has not been comprehensively evaluated in ccRCC. To assess the involvement of HAF/HIFs in ccRCC, we analyzed their relationship to tumor grade/stage/outcome using tissue from 380 patients, and validated these associations using tissue from 72 additional patients and a further 57 patients treated with antiangiogenic therapy for associations with response. Further characterization was performed using single-cell mRNA sequencing (scRNA-seq), RNA- HIF-1α was primarily expressed in tumor-associated macrophages (TAMs), whereas HIF-2α and HAF were expressed primarily in tumor cells. TAM-associated HIF-1α was significantly associated with high tumor grade and increased metastasis and was independently associated with decreased overall survival. Furthermore, elevated TAM HIF-1α was significantly associated with resistance to antiangiogenic therapy. In contrast, high HAF or HIF-2α were associated with low grade, decreased metastasis, and increased overall survival. scRNA-seq, RNA-ISH, and Western blotting confirmed the expression of HIF-1α in M2-polarized CD163-expressing TAMs. These findings highlight a potential role of TAM HIF-1α in ccRCC progression and support the reevaluation of HIF-1α as a therapeutic target and marker of disease progression.
Identifiants
pubmed: 32586940
pii: 1078-0432.CCR-19-3890
doi: 10.1158/1078-0432.CCR-19-3890
pmc: PMC7968518
mid: NIHMS1607780
doi:
Substances chimiques
Basic Helix-Loop-Helix Transcription Factors
0
Biomarkers, Tumor
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
endothelial PAS domain-containing protein 1
1B37H0967P
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
4970-4982Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA217905
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA030199
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA224917
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181106
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
©2020 American Association for Cancer Research.
Références
Trends Biochem Sci. 2012 Sep;37(9):364-72
pubmed: 22818162
Cancer Res. 2015 Jan 15;75(2):316-29
pubmed: 25421578
PLoS Biol. 2003 Dec;1(3):E83
pubmed: 14691554
Mol Cancer Ther. 2008 Jan;7(1):90-100
pubmed: 18202012
Blood. 2010 Oct 21;116(16):3039-48
pubmed: 20628150
Mol Cell Biol. 2005 Jul;25(13):5675-86
pubmed: 15964822
Nat Cell Biol. 2016 Apr;18(4):356-65
pubmed: 27027486
Science. 2018 Aug 10;361(6402):594-599
pubmed: 30093597
Cancer Cell. 2016 Oct 10;30(4):515-517
pubmed: 27728802
Nature. 2016 Nov 3;539(7627):107-111
pubmed: 27595393
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
Cancer Cell. 2008 Dec 9;14(6):435-46
pubmed: 19061835
Cancer Cell. 2002 Jun;1(5):459-68
pubmed: 12124175
BMC Cancer. 2015 Aug 08;15:577
pubmed: 26253167
Nature. 2016 Nov 3;539(7627):112-117
pubmed: 27595394
Cancer Res. 2011 Jun 1;71(11):4015-27
pubmed: 21512133
Int J Cancer. 2016 Mar 1;138(5):1058-66
pubmed: 25784597
J Orthop Res. 2014 Aug;32(8):975-80
pubmed: 24677016
Cancer Res. 2010 Dec 15;70(24):10101-11
pubmed: 21159632
Proc Natl Acad Sci U S A. 2014 Feb 18;111(7):2698-703
pubmed: 24497508
Am J Respir Cell Mol Biol. 2016 Dec;55(6):889-898
pubmed: 27494303
Nat Commun. 2019 Mar 8;10(1):1146
pubmed: 30850588
Int J Cancer. 2012 Dec 15;131(12):2785-94
pubmed: 22505354
Cancer Immunol Res. 2019 Jul;7(7):1091-1105
pubmed: 31164356
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Anticancer Res. 2015 Jan;35(1):433-8
pubmed: 25550584
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
PeerJ. 2017 Nov 17;5:e4065
pubmed: 29158991
Front Oncol. 2018 Jun 11;8:224
pubmed: 29942795
Genes Dev. 2010 Mar 1;24(5):491-501
pubmed: 20194441
Int J Cancer. 2015 Apr 1;136(7):1504-14
pubmed: 25123505
Mol Cell Biol. 2003 Dec;23(24):9361-74
pubmed: 14645546
Eur J Med Chem. 2012 Mar;49:24-40
pubmed: 22305612
Mol Cancer Res. 2019 May;17(5):1220-1232
pubmed: 30705246
PLoS One. 2012;7(1):e31034
pubmed: 22299048
J Mol Med (Berl). 2014 Aug;92(8):825-36
pubmed: 24916472
Eur J Cancer. 2014 May;50(8):1531-40
pubmed: 24565854
Nat Rev Cancer. 2011 Jun;11(6):393-410
pubmed: 21606941
Crit Rev Oncol Hematol. 2017 Mar;111:117-123
pubmed: 28259286
Cancer Discov. 2011 Aug;1(3):222-35
pubmed: 22037472
Mol Cell Biol. 2008 Dec;28(23):7081-95
pubmed: 18838541
Nat Genet. 1994 May;7(1):85-90
pubmed: 7915601
Immunity. 2014 Nov 20;41(5):815-29
pubmed: 25453823
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902